Vol. 6, Issue 1, Part B (2024)

This review provides a comprehensive analysis of two prominent heart failure treatments, Ivabradine and Sacubitril/Valsartan, highlighting their distinct mechanisms and clinical efficacy. Ivabradine primarily reduces heart rate by inhibiting the funny current in the sinoatrial node, offering benefits particularly in chronic heart failure patients with elevated heart rates. On the other hand, Sacubitril/Valsartan, an ARNI, has shown significant benefits in reducing mortality and hospitalization rates in heart failure with reduced ejection fraction (HFrEF), but its effects in HFpEF and HFmrEF are less conclusive. While Sacubitril/Valsartan offers a ground-breaking approach in heart failure treatment, it also presents an increased risk of hypotension. This review suggests that the choice of therapy should be tailored to individual patient profiles to optimize outcomes in heart failure management.